Mirxes Unit Forms JV Firm for Cancer Detection Testing

MT Newswires Live

Oct 06

Mirxes (HKG:2629) unit Mirxes International entered into an agreement with Xeraya Opportunities Fund PCC to form a joint venture named MYRNA DIAGNOSTICS, a Monday Hong Kong bourse filing said.

The two parties will contribute $2 million and $3 million to the JV firm and hold a 40% and 60% stake, respectively, according to the micro ribonucleic acid technology company.

The JV company will engage in the R&D, commercialization, and obtaining of regulatory approval for cancer early detection and other nucleic acid-based tests in Malaysia.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573085676"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573085676\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573085676?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 18:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573085676","market":"sg","top_or_hot":-1,"title":"Mirxes Unit Forms JV Firm for Cancer Detection Testing","media":"MT Newswires Live","content":"<html><body><p> Mirxes (HKG:2629) unit Mirxes International entered into an agreement with Xeraya Opportunities Fund PCC to form a joint venture named MYRNA DIAGNOSTICS, a Monday Hong Kong bourse filing said.</p><p>The two parties will contribute $2 million and $3 million to the JV firm and hold a 40% and 60% stake, respectively, according to the micro ribonucleic acid technology company.</p><p>The JV company will engage in the R&amp;D, commercialization, and obtaining of regulatory approval for cancer early detection and other nucleic acid-based tests in Malaysia.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mirxes Unit Forms JV Firm for Cancer Detection Testing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMirxes Unit Forms JV Firm for Cancer Detection Testing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-06 18:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Mirxes (HKG:2629) unit Mirxes International entered into an agreement with Xeraya Opportunities Fund PCC to form a joint venture named MYRNA DIAGNOSTICS, a Monday Hong Kong bourse filing said.</p><p>The two parties will contribute $2 million and $3 million to the JV firm and hold a 40% and 60% stake, respectively, according to the micro ribonucleic acid technology company.</p><p>The JV company will engage in the R&amp;D, commercialization, and obtaining of regulatory approval for cancer early detection and other nucleic acid-based tests in Malaysia.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2573085676","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573085676","pubTimestamp":1759747786,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mirxes  unit Mirxes International entered into an agreement with Xeraya Opportunities Fund PCC to form a joint venture named MYRNA DIAGNOSTICS, a Monday Hong Kong bourse filing said.The two parties will contribute $2 million and $3 million to the JV firm and hold a 40% and 60% stake, respectively, according to the micro ribonucleic acid technology company.The JV company will engage in the R&D, commercialization, and obtaining of regulatory approval for cancer early detection and other nucleic acid-based tests in Malaysia.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02629":"MIRXES-B"},"translate_title":"Mirxes部门成立癌症检测测试合资公司","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02629":1.5},"content_text":"Mirxes (HKG:2629) unit Mirxes International entered into an agreement with Xeraya Opportunities Fund PCC to form a joint venture named MYRNA DIAGNOSTICS, a Monday Hong Kong bourse filing said.The two parties will contribute $2 million and $3 million to the JV firm and hold a 40% and 60% stake, respectively, according to the micro ribonucleic acid technology company.The JV company will engage in the R&D, commercialization, and obtaining of regulatory approval for cancer early detection and other nucleic acid-based tests in Malaysia.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}